Semaglutide

What is Semaglutide?

Semaglutide is a synthetic 31-amino-acid analogue of human glucagon-like peptide-1 (GLP-1), a gut incretin hormone, engineered as a long-acting GLP-1 receptor agonist. It is built on the GLP-1(7-37) backbone with two amino-acid substitutions (2-aminoisobutyric acid at position 8 and arginine at position 34) and a C18 fatty diacid attached at lysine 26 through a linker. These changes protect the peptide from dipeptidyl peptidase-4 (DPP-4) cleavage and promote albumin binding, giving it a plasma half-life of roughly one week in published studies.

Semaglutide is the peptide studied in several licensed medicines and is one of the most cited compounds in the GLP-1 research literature. GenoPept supplies semaglutide as a research peptide for UK laboratories investigating incretin biology, receptor pharmacology and metabolic models. It is strictly for in-vitro research use and is not a medicine.

Semaglutide research applications

Semaglutide is investigated across a wide range of preclinical and cell-culture settings. The areas below reflect published research directions, not outcomes for people.

Incretin and glucose metabolism models

Semaglutide is widely used as a reference GLP-1 receptor agonist in pancreatic beta-cell lines and rodent models of glucose handling, where research explores glucose-dependent insulin secretion, glucagon suppression and islet function.

Energy balance and adiposity research

In diet-induced obesity models, the peptide has been investigated for its effects on food intake, body weight and adipose tissue biology, and is frequently used as a comparator when newer dual or triple agonists are assessed.

Cardiovascular and renal biology

Preclinical work examines the compound in models of atherosclerosis, vascular inflammation and kidney injury, with research exploring whether GLP-1 receptor signalling influences lipid handling and inflammatory pathways.

Hepatic steatosis and liver models

Semaglutide is studied in animal models of fatty liver and steatohepatitis, where liver fat content, fibrosis markers and hepatocyte signalling are the typical readouts.

Neuroscience and appetite circuitry

Research explores how semaglutide engages GLP-1 receptors in the hypothalamus and brainstem, and its effects on neuroinflammation and neuronal survival in models of neurodegeneration.

Mechanism of action (preclinical)

Semaglutide binds and activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, neurons, cardiomyocytes and other tissues. Receptor activation stimulates adenylyl cyclase, raising intracellular cyclic AMP and activating protein kinase A and Epac2, which in beta cells potentiates glucose-dependent insulin exocytosis.

In preclinical models semaglutide also slows gastric emptying, reduces glucagon release and acts on central appetite centres to reduce food intake. Its extended half-life results from albumin binding through the C18 diacid side chain and from resistance to DPP-4 degradation conferred by the Aib8 substitution.

Semaglutide product specifications

Available sizes

Semaglutide is available in the following vial sizes:

• 5mg vial
• 10mg vial
• 15mg vial
• 20mg vial
• 30mg vial
• 40mg vial
• 50mg vial

Laboratories that need larger quantities can order in bulk boxes of 10 vials, which save 20–50% against single-vial pricing. Retail orders also receive automatic discounts at £300, £500 and £1,000, and delivery is free on UK orders of £200 or more.

Reconstitution, handling and storage (laboratory)

Unopened Semaglutide vials should be stored at −20 °C for long-term storage, or at 2–8 °C for short periods, and protected from light. Allow the vial to reach room temperature before opening to avoid condensation on the lyophilised cake.

To reconstitute for in-vitro work, add bacteriostatic water or another sterile diluent slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Do not shake, as agitation can damage large acylated peptides. Reconstituted solution should be kept at 2–8 °C and used within the period specified in the laboratory’s own protocol. See our guides on how to reconstitute research peptides and how to store research peptides for step-by-step handling notes.

Quality assurance and Certificate of Analysis

Purity and identity results are batch-specific. Consult the applicable supplied report for its results and methods; confirm the batch covers current stock and verify the laboratory’s accreditation scope directly.

Use the “View Certificate of Analysis” button on this page to open the current batch COA, or browse the full COA library. Our article on what a Certificate of Analysis shows explains how to read the chromatogram and mass spectrum.

Related research compounds

• Tirzepatide: the dual GIP/GLP-1 receptor agonist most often compared with semaglutide in metabolic models.
• Retatrutide: a triple GIP/GLP-1/glucagon receptor agonist for next-generation incretin research.
• Liraglutide: the earlier once-daily GLP-1 analogue, useful as a shorter-acting comparator.
• Cagrilintide + Semaglutide Blend: for co-investigation of amylin and GLP-1 receptor pathways.

Semaglutide frequently asked questions

What is semaglutide used for in research?

Semaglutide is used in laboratories as a reference GLP-1 receptor agonist. Published preclinical research applies it in models of glucose metabolism, energy balance, fatty liver, cardiovascular biology and neuroscience, and it is a standard comparator when newer incretin-based peptides are evaluated. It is supplied for these in-vitro and preclinical research uses only, not for any human application.

How is semaglutide supplied and what purity can I expect?

Purity and identity results are batch-specific. Consult the applicable supplied report for its results and methods; confirm the batch covers current stock and verify the laboratory’s accreditation scope directly.

How should semaglutide be stored?

Store unopened vials at minus 20 degrees Celsius for long-term storage, or at 2 to 8 degrees Celsius for short periods, and keep them protected from light. Once reconstituted with bacteriostatic water or sterile diluent, hold the solution at 2 to 8 degrees Celsius and use it within the timeframe defined in your laboratory protocol.

Is semaglutide from GenoPept for human use?

No. This product is sold by GenoPept strictly for in-vitro laboratory research. It is not a medicine, has not been prepared under pharmaceutical GMP for administration, and must not be used for human or veterinary purposes, diagnosis or therapy. Purchasers are responsible for handling it in accordance with UK research use only requirements.

What is the difference between semaglutide and tirzepatide?

Semaglutide is a selective GLP-1 receptor agonist, whereas tirzepatide activates both the GIP and GLP-1 receptors. Both are long-acting acylated peptides, but tirzepatide is a 39-amino-acid sequence and semaglutide has 31 residues. Researchers often run them side by side to separate single-receptor effects from dual-incretin signalling. See our semaglutide vs tirzepatide vs retatrutide comparison.

Research use only. Semaglutide is supplied by GenoPept strictly for in-vitro laboratory research. It is not a medicine, is not for human or veterinary use, and is not intended for diagnostic or therapeutic purposes. Read our research use only policy and UK legal guide before ordering.